文摘
摘要目的:评估neurofilament-light链(sNfL)的预测价值的风险疾病活动的证据(EDA)和临床转换(CC)的放射检查孤立综合症患者(RIS)。
背景:EDA(新MRI病灶和/或临床事件)是多发性硬化症(MS)的特征,与复发的风险增加有关。除了年轻,男性和脊髓病变(s),高架脑脊液(CSF) NfL和存在免疫球蛋白G寡克隆乐队(时常)最近被确定为预测的CC RIS科目。
设计/方法:我们测量sNfL和CSF NfL水平由单分子阵列(RIS Simoa Quanterix)患者2009 RIS所定义的标准。我们分析的影响,年龄、性别、2005传播空间(DIS)标准,脊髓损伤,gadolinium-enhanced病变,台籍干部,sNfL和CSF NfL EDA和CC使用kaplan meier的风险分析和Cox回归模型。
结果:62年RIS患者包括从4 MS中心。平均随访时间是45个月。CSF NfL在包容和sNfL水平高度相关(枪兵,r = 0.783)。kaplan meier分析显示,台籍干部,CSF NfL > 400 pg / mL, sNfL > 6.5 pg / mL和4/4 2005说的标准是预测疾病的活动(日志等级,p = 0.017, p = 0.022, p = 0.025, p = 0.45)。患者尤其是4/4 2005说标准和/或sNfL > 6.5 pg / mL有86%的风险EDA 54%没有这些特征。随访期间只有CSF NfL水平预测CC(日志级别,p = 0.033)。多变量Cox回归模型显示,台籍干部,MRI标准和sNfL > 6.5 pg / mL是EDA的独立因素(HR = 1.87, p = 0.047;HR = 2.21, p = 0.025和HR = 2.19, p = 0.019,分别),但不是CC。
结论:sNfL升高,台籍干部和2005核磁共振标准预测RIS的EDA。如果复制在较大的数据集,这些生物标记物可能对治疗决定通知在这个人口高度相关。
代表RISC和SFSEP。
披露:Thouvenot博士没有披露。Demattei博士没有披露。Uygunoglu博士没有披露。Pittion博士没有披露。Castelnovo博士没有披露。杜博士Trieu de Terdonck没有披露。科恩博士没有披露。奥田硕博士已经收到个人赔偿咨询、担任科学顾问委员会说,或其他活动收到Celgene公司咨询和咨询费,EMD Serono,基因泰克,Genzyme,诺华。奥田硕博士接到生原体研究支持。Kantarci博士已经收到个人赔偿咨询、担任科学顾问委员会说,诺华制药和生原体或其他活动。 Dr. Kantarci has received research support from Biogen, the Multiple Sclerosis Society, the Mayo Foundation, and the Hilton Foundation. Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Marin has nothing to disclose. Dr. Lehmann has nothing to disclose. Dr. Siva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novarti Pharmaceuticals, Teva, Sanofi Genzyme, Bayer, and Roche. Dr. Lebrun Frenay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer Schering, Biogen, Genzyme, Merck Serono, Novartis Pharmaceuticals, and Teva.
